Log in
Enquire now
Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.

OverviewStructured DataIssuesContributorsActivity

Contents

palvellatx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biotechnology
Biotechnology
Drug discovery
Drug discovery
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
Technology
Technology
Biology
Biology
Healthcare
Healthcare
...
Location
Wayne, Pennsylvania
Wayne, Pennsylvania
B2X
B2B
B2B
CEO
Wes Kaupinen
Wes Kaupinen
0
Founder
Wes Kaupinen
Wes Kaupinen
Pitchbook URL
pitchbook.com/profiles...184764-61
Legal Name
Palvella Therapeutics, Inc.
Legal classification
Corporation
Corporation
Date Incorporated
2015
Number of Employees (Ranges)
1 – 10
Email Address
info@palvellatx.com
Phone Number
+14842531460
Full Address
125 Strafford Avenue Suite 360 Wayne, PA 19087 United States
CIK Number
1,742,961
Place of Incorporation
Delaware
Delaware
Investors
Adams Street Partners
Adams Street Partners
Ligand Pharmaceuticals
Ligand Pharmaceuticals
‌
Opaleye Management
BioAdvance
BioAdvance
Samsara BioCapital
Samsara BioCapital
‌
CAM Capital
‌
BVF Partners
Agent Capital
Agent Capital
...
Founded Date
2015
Total Funding Amount (USD)
55,000,000
Latest Funding Round Date
May 29, 2020
Key People
‌
Lorne Cheeseman
‌
Emily Cook
Wes Kaupinen
Wes Kaupinen
‌
Jordan Houtz
‌
Laura Rice
‌
Cory Freedland
‌
Scott Morenstein
Latest Funding Type
Series C
Series C
Patents Assigned (Count)
5
Country
United States
United States

Other attributes

Company Operating Status
Active
Funding Type
Series C
Series C
Latest Funding Round Amount (USD)
45,000,000
Public/Private
Private

Palvella Therapeutics is a start-up life sciences company in Pennsylvania that focuses on serving abandoned patient populations with therapies. Founded 2015 in Wayne, Pennsylvania, United States by Wes Kaupinen, Palvella Therapeutics has raised a total of $59.4M in funding over four rounds. Their latest funding was raised on May 28, 2020 from a series C round. Palvella Therapeutics is funded by 10 investors, with Opaleye Management and BioAdvance are the most recent investors. The company is engaged in developing novel, disease-modifying therapies to treat pachyonychia congenita, an ultra-orphan and chronically-debilitating genetic disease for which no treatments currently exist. These treatments enable patients to get the best treatment for diseases and lead a better life.

Derived from the Finnish word for "to serve", Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Palvella Therapeutics, Inc.

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.